These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 19399720)

  • 1. [GnRH antagonists--a new therapy option for advanced prostate cancer].
    Wolff JM
    Aktuelle Urol; 2009 May; 40(3):159-63. PubMed ID: 19399720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testosterone surge: rationale for gonadotropin-releasing hormone blockers?
    van Poppel H; Nilsson S
    Urology; 2008 Jun; 71(6):1001-6. PubMed ID: 18407326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gonadotropin-releasing hormone: an update review of the antagonists versus agonists.
    Van Poppel H; Klotz L
    Int J Urol; 2012 Jul; 19(7):594-601. PubMed ID: 22416801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer.
    Kirby RS; Fitzpatrick JM; Clarke N
    BJU Int; 2009 Dec; 104(11):1580-4. PubMed ID: 20053189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer.
    Steinberg M
    Clin Ther; 2009; 31 Pt 2():2312-31. PubMed ID: 20110043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen deprivation therapy: past, present and future.
    Schröder F; Crawford ED; Axcrona K; Payne H; Keane TE
    BJU Int; 2012 Jun; 109 Suppl 6():1-12. PubMed ID: 22672120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer.
    Boccon-Gibod L; Iversen P; Persson BE
    Expert Rev Anticancer Ther; 2009 Dec; 9(12):1737-43. PubMed ID: 19954284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of advanced prostate cancer: can we improve on androgen deprivation therapy?
    Anderson J; Abrahamsson PA; Crawford D; Miller K; Tombal B
    BJU Int; 2008 Jun; 101(12):1497-501. PubMed ID: 18336613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist.
    Princivalle M; Broqua P; White R; Meyer J; Mayer G; Elliott L; Bjarnason K; Haigh R; Yea C
    J Pharmacol Exp Ther; 2007 Mar; 320(3):1113-8. PubMed ID: 17179469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
    Garnick MB; Mottet N
    BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Degarelix: a new approach for the treatment of prostate cancer.
    Persson BE; Kold Olesen T; Jensen JK
    Neuroendocrinology; 2009; 90(3):235-44. PubMed ID: 19602868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open-label study of abarelix in men with symptomatic prostate cancer at risk of treatment with LHRH agonists.
    Koch M; Steidle C; Brosman S; Centeno A; Gaylis F; Campion M; Garnick MB;
    Urology; 2003 Nov; 62(5):877-82. PubMed ID: 14624912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Degarelix (firmagon) for prostate cancer.
    Med Lett Drugs Ther; 2009 Oct; 51(1323):82-3. PubMed ID: 19838145
    [No Abstract]   [Full Text] [Related]  

  • 14. Luteinizing hormone-releasing hormone antagonists in prostate cancer.
    Stricker HJ
    Urology; 2001 Aug; 58(2 Suppl 1):24-7. PubMed ID: 11502441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gonadotropin-releasing hormone antagonist: A real advantage?
    Kimura T; Sasaki H; Akazawa K; Egawa S
    Urol Oncol; 2015 Jul; 33(7):322-8. PubMed ID: 26070474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Will GnRH antagonists improve prostate cancer treatment?
    Huhtaniemi I; White R; McArdle CA; Persson BE
    Trends Endocrinol Metab; 2009 Jan; 20(1):43-50. PubMed ID: 19008119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bench-to-bedside development of agonists and antagonists of luteinizing hormone-releasing hormone for treatment of advanced prostate cancer.
    Rick FG; Schally AV
    Urol Oncol; 2015 Jun; 33(6):270-4. PubMed ID: 25512159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological treatment of patients with advanced prostate cancer.
    Turner B; Drudge-Coates L
    Nurs Stand; 2014 Feb; 28(23):44-8. PubMed ID: 24494915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of LHRH antagonists for advanced prostate cancer.
    Moul JW
    Can J Urol; 2014 Apr; 21(2 Supp 1):22-7. PubMed ID: 24775720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.